anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: Data indicates that clinicians might be under-prescribing opioids for patients with chronic cancer pain, and this could impact adequate pain management. Few studies have sought to understand healthcare provider (HCP) perceptions and practices regarding the prescription of opioids for chronic cancer pain. We assessed HCP perceptions and practices regarding opioid prescription for patients with chronic cancer pain since the onset of the COVID-19 pandemic.
METHODS: An anonymous cross-sectional survey was conducted among 186 HCPs who attended an opioid educational event in April 2021 and 2022.
RESULTS: Sixty-one out of 143 (44%) opioid prescribers reported reluctance to prescribe opioids for chronic cancer pain. In a multivariate logistic model, younger participants (log OR - 0.04, 95% CI - 0.085, - 0.004; p = 0.033) and pain medicine clinicians (log OR - 1.89, CI - 3.931, - 0.286; p = 0.034) were less reluctant, whereas providers who worry about non-medical opioid use were more reluctant to prescribe opioids (log OR 1.58 95% CI 0.77-2.43; p < 0.001). Fifty-three out of 143 (37%) prescribers had experienced increased challenges regarding opioid dispensing at pharmacies, and 84/179 (47%) of all respondents reported similar experience by their patients. Fifty-four out of 178(30%) were aware of opioid-related harmful incidents to patients or their families, including incidents attributed to opioid misuse by a household or family member.
CONCLUSION: A considerable number of opioid prescribers were reluctant to prescribe opioids for patients with chronic cancer pain. Many reported challenges regarding dispensing of opioids at the pharmacies. These may be unintended consequences of policies to address the opioid crisis. Future measures should focus on addressing regulatory barriers without undermining the gains already made to combat the opioid crisis.
The surgical site selected for performing the thoracoscopy will be cleaned with 4%w/v chlorhexidine gluconate solution for 3 minutes. This will then be washed with normal saline and a sterile gauge. After drying chlorhexidine gluconate (2.5%v/v)-ethanol IP (70%v/v) will be applied and allowed to dry for 3 minutes before the incision.
PURPOSE: To obtain an aq. hair setting compsn. contg. alginate hair setting resin and a polymer having a carboxylic acid part in each monomeric unit and hard to peel from hair. CONSTITUTION: This hair setting compsn. is stable at room temp. for at least one month and contains 0.1-10% alginate hair setting resin (A) such as alkali metallic alginate, ammonium alginate, ethylene or propylene glycol alginate, 0.1-10% polymer (B) having at least one carboxylic acid part in each monomeric unit, e.g. poly(meth)acrylic acid optionally cross-linked with allyl ether of pentaerythritol or allyl ester of sucrose and 0.2-80% aq. vehicle (C). The weight ratio of A:B is 1:1 to 5:1, preferably 2:1 to 3:1. This hair setting compsn. is preferably used in the form of an aerosol compsn. consisting essentially of 75-95% of the hair setting compsn. and 3-25% propellent.
Patients receive zoledronic acid IV at months 1 and 6. Beginning 14 days after first zoledronic acid infusion, patients receive oral letrozole once daily for 12 months in the absence of disease progression or unacceptable toxicity.
Interpretive criteria for urinary isolates have not been established for Proquin XR. Interpretive criteria established based on systemic drug levels may not be appropriate for uncomplicated urinary tract infections.

Dilution Techniques: Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on a dilution method1 (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of ciprofloxacin powder. The MIC values should be interpreted according to the following criteria:

For testing Enterobacteriaceae:

A report of "Susceptible" indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentration usually achievable. A report of "Intermediate" indicates that the result should be considered equivocal, and if the microorganism is not fully-susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of "Resistant" indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentration usually achievable; other therapy should be selected.

Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures. Standard ciprofloxacin powder should provide the following MIC values:

Diffusion Techniques: Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure2 requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 5-mcg ciprofloxacin to test the susceptibility of microorganisms to ciprofloxacin.

Reports from the laboratory providing results of the standard single-disk susceptibility test with a 5-mcg ciprofloxacin disk should be interpreted according to the following criteria:

For testing Enterobacteriaceae:

Interpretation should be as stated above for results using dilution techniques. Interpretation involves correlation of the diameter obtained in the disk test with the MIC for ciprofloxacin.

As with standardized dilution techniques, diffusion methods require the use of laboratory control microorganisms that are used to control the technical aspects of the laboratory procedures. For the diffusion technique, the 5-mcg ciprofloxacin disk should provide the following zone diameters in these laboratory quality control strains:
Osteonecrosis of the jaw is the progressive loss and destruction of bone affecting the maxilla or mandible in patients treated with antiresorptive and antiangiogenic agents without receiving prior radiation therapy. The pathogenesis involves the inflammatory pathway of receptor activator of nuclear factor NF-kB ligand and the macrophage colony-stimulating factor, essential for osteoclast precursors survival and proliferation and acting through its receptor c-Fms. Evidence has shown the role of non-coding RNAs in the pathogenesis of osteonecrosis of the jaw and this finding might be useful in diagnosis since these small RNAs could be considered as biomarkers of apoptotic activity in bone. Interestingly, it has been proved that miR-29 and miR-31-5p, acting on specific targets such as CALCR and RhoA, promote programmed-cell death and consequently the necrosis of bone tissue. Specific long non-coding RNAs, instead, have been detected both at reduced levels in patients with multiple myeloma and osteonecrosis, and associated with suppression of osteoblast differentiation, with consequences in the progression of mandible lesions. Among non-coding genic material, circular RNAs have the capability to modify the expression of specific mRNAs responsible for the inhibition of bisphosphonates activity on osteoclastogenesis.
Currently, patients with recurrent or primary refractory non-Hodgkin's lymphoma are treated with second-line chemotherapy (usually 2-3 courses) for the purpose of cytoreduction and to establish sensitivity to chemotherapy. Thereafter, peripheral blood progenitor cells are mobilized with cyclophosphamide and granulocyte colony stimulating factor, apheresed and cryopreserved. The standard high dose regimen consists of augmented carmustine, etoposide and cyclophosphamide. Unfortunately, there are subgroups of patients with poor outcomes using autologous transplantation including those with transformed lymphoma as well as patients who do not attain a minimal disease state due to chemoresistant disease.

These groups of patients have limited disease control and survival with standard chemotherapy regimens, and although they often have excellent cytoreduction with the high-dose chemotherapy regimen, relapse remains the primary cause of treatment failure. The current trial utilizes a similar approach that has been taken with patients with multiple myeloma, who appear to benefit from an allogeneic graft-versus-tumor effect, using a combined autologous and non-myeloablative allogeneic transplant regimen to reduce transplant-related complications. Eligible patients will be treated with high-dose chemotherapy using BCNU, etoposide and cyclophosphamide with autologous hematopoietic cell support as a method of cytoreduction. Approximately 60-120 days after the autologous transplant, patients will receive an allogeneic transplant using a preparative regimen of total lymphoid irradiation and anti-thymocyte globulin in an attempt to develop a graft-versus-lymphoma effect.
Animal-assisted therapies are an innovative strategy within health care humanization initiatives, and they could play a role in the reduction of pain or anxiety. The main objective of this work was to evaluate the feasibility of implementing animal-assisted therapy in a pediatric intensive care unit and its effectiveness for the reduction of pain, fear, and anxiety. A prospective, quasi-experimental study of animal-assisted therapy was designed in the pediatric intensive care unit of the Hospital Universitario 12 de Octubre of Madrid, from January 2019 to December 2019. The study sample included patients who had been admitted to the unit and were over 3 years old. Satisfaction surveys were collected from the patients, family, and health personnel involved. Physiological variables and the level of pain (visual analog scale or Wong-Baker scale), fear (Child Medical Fear Scale), and anxiety (modified Yale Preoperatory Anxiety Scale) were evaluated before and after each session. Any existence of adverse events was recorded. A total of 74 therapy sessions were performed on 61 patients. All sessions were completed without any adverse effects. A total of 164 surveys were collected, providing an overall project rating of 9.69 out of a possible 10. The survey comments were found to be positive in most cases. No differences were found in the physiological variables measured before and after each session. There was a statistically significant decrease in pain, fear, and anxiety levels (p < 0.01).   Conclusion: The implementation of an animal-assisted therapy project in a pediatric intensive care unit is feasible and safe and has a high degree of acceptance among both participants and healthcare staff. Animal-assisted therapy is effective for the reduction of pain, fear, and anxiety, and therefore, it could be considered an adjunct to non-pharmacological therapy. What is Known: • Animal assisted therapies (AAT) are an innovative strategy that could be beneficial to help pediatrics patients cope with admission difficulties and could even play a role in reducing pain, anxiety and/or delirium. • To date there are not studies to analyze the effectiveness of AAT in the field of Pediatric Intesive Care. What is New: • Our study confirms the feasibility and effectiveness of the implementation of an AAT in the field of Pediatric Intensive Care with a high degree of acceptance by participants, caregivers and healthcare personnel. • AAT demonstrated a reduction in pain, fear and anxiety in pediatrics patients admitted to Pediatric Intensive Care Unit.
The invention discloses a Chinese medicinal composition for treating respiratory diseases of livestock and a preparation method thereof, and relates to a Chinese medicinal composition for treating diseases of the livestock, particularly the respiratory diseases. The Chinese medicinal composition comprises the following components based on every 100 weight parts: 58 to 68 parts of indigowoad root, 4 to 10 parts of toad venom, 3 to 8 parts of synthetic bezoar, 7 to 13 parts of porcine bile paste powder, 1 to 5 parts of liquorice, 1 to 4 parts of indigo naturalis, 1 to 5 parts of compound of glauber-salt and liquorice, 1 to 3 parts of borneol, 4 to 10 parts of realgar, and 3 to 7 parts of astragalus. The method for preparing the medicinal composition is unique. The medicament of astragalus is increased on the basis of the traditional prescription. Besides the effects of effectively preventing and controlling various respiratory diseases of the livestock, the medicinal composition has better treatment effect on phlegmatic and ropy livestock, can also increase the antibodies, and improves the immunity of the livestock. The medicinal composition is pure Chinese medicament preparation, has no side effect, can fully utilize domestic Chinese medicament resources, particularly has no residue in the livestock body after administration, and can further effectively solve the problem of animal product safety.
14.1 Treatment of Hypoxic Respiratory Failure (HRF)

The efficacy of nitric oxide has been investigated in term and near-term newborns with hypoxic respiratory failure resulting from a variety of etiologies. Inhalation of nitric oxide reduces the oxygenation index (OI= mean airway pressure in cm H2O × fraction of inspired oxygen concentration [FiO2]× 100 divided by systemic arterial concentration in mm Hg [PaO2]) and increases PaO2 [see Clinical Pharmacology (12.1)].

14.3 Ineffective in Prevention of Bronchopulmonary Dysplasia (BPD)

The safety and efficacy of nitric oxide for the prevention of chronic lung disease [bronchopulmonary dysplasia, (BPD)] in neonates ≤ 34 weeks gestational age requiring respiratory support has been studied in four large, multi-center, double-blind, placebo-controlled clinical trials in a total of 2,600 preterm infants. Of these, 1,290 received placebo, and 1,310 received inhaled nitric oxide at doses ranging from 5-20 ppm, for treatment periods of 7-24 days duration. The primary endpoint for these studies was alive and without BPD at 36 weeks postmenstrual age (PMA). The need for supplemental oxygen at 36 weeks PMA served as a surrogate endpoint for the presence of BPD. Overall, efficacy for the prevention of bronchopulmonary dysplasia in preterm infants was not established. There were no meaningful differences between treatment groups with regard to overall deaths, methemoglobin levels, or adverse events commonly observed in premature infants, including intraventricular hemorrhage, patent ductus arteriosus, pulmonary hemorrhage, and retinopathy of prematurity.

The use of nitric oxide for prevention of BPD in preterm neonates ≤ 34 weeks gestational age is not recommended.
The invention discloses a Chinese medicinal compound preparation for treating hyperglycemia. The Chinese medicinal compound preparation is prepared from the following Chinese medicinal raw materials by weight: 23-34g of radix notoginseng, 23-34g of leeches and 3-4g of herb of rosemary. The Chinese medicinal raw materials are mixed and ground into fine powder, and pills can be prepared from the fine powder. The Chinese medicinal compound preparation can be granules, tablets and capsules sharing the same Chinese medicinal formula. The three Chinese medicinal herbs are mixed and ground into powder to complement one another in function and to be improved in efficacies and effects of accelerating the melting of fatty speckles and returning the blood sugar to normal, and the three Chinese medicinal herbs have significant effects on treating hyperglycemia. The Chinese medicinal compound preparation has the characteristics of simple formula, low cost, short course of treatment, significant treatment effect and no side or toxic effects, is convenient to prepare, is safe and reliable and can bring great benefits to patients with hyperglycemia.
Disclosed are a SARS-COV-2 antigen polypeptide, a recombinant adeno-associated virus (rAAV) expressing the polypeptide, and a vaccine containing the virus. A sequence of the antigen polypeptide is shown in SEQ NO. 1. and SEQ ID NO. 2. A method for preparing the recombinant adeno-associated virus comprises co-incubating pHelper, pRep2Cap5, and an expression vector, transfecting a cell in the presence of polyethyleneimine as a transfection reagent; culturing the cell, then collecting the cell by centrifugation, performing lysis and purification to obtain a purified liquid comprising the recombinant adeno-associated virus. The rAAV is delivered and expressed in vivo to produce a fusion antigen polypeptide, induces the production of serum neutralizing antibodies, which have a neutralizing titer to the novel SARS-COV-2 coronavirus and are expressed continuously; the rAAV composition can be used to immunize humans against the novel coronavirus pneumonia COVID-19.
Anuria. Severe or progressive kidney disease or dysfunction, with the possible exception of nephrosis. Severe hepatic disease. Hypersensitivity to the drug or any of its components.

Dyrenium (triamterene) should not be used in patients with pre-existing elevated serum potassium, as is sometimes seen in patients with impaired renal function or azotemia, or in patients who develop hyperkalemia while on the drug. Patients should not be placed on dietary potassium supplements, potassium salts or potassium-containing salt substitutes in conjunction with Dyrenium.

Dyrenium should not be given to patients receiving other potassium-sparing agents, such as spironolactone, amiloride hydrochloride, or other formulations containing triamterene. Two deaths have been reported in patients receiving concomitant spironolactone and Dyrenium or Dyazide®. Although dosage recommendations were exceeded in one case and in the other serum electrolytes were not properly monitored, these two drugs should not be given concomitantly.
The present invention relates to an oral suspension of tadalafil comprising 0.01% to 5% w/v tadalafil, cyclodextrin, co-processed microcrystalline cellulose and sodium carboxymethyl cellulose, xanthan gum and water as carrier. The suspension is chemically and physically stable and shows a dissolution profile comparable to that of commercial tadalafil film coated tablets. Tadalafil suspension is useful for treating male erectile dysfunction and benign prostatic hyperplasia. The invention also relates to a fixed dose combination dosage form comprising said tadalafil suspension and tamsulosin (in particular in the form of a release-modifying pellet) or dutasteride. The combination is useful for treating lower urinary tract symptoms associated with benign prostatic hyperplasia. The invention also relates to a process for preparing said tadalafil composition.
599297 Disclosed is a computer-implemented method to assist a dispatcher (104) when communicating with a caller (118) via telephone (116) regarding a medical emergency of a patient. A dispatch center computer system (106) provides an emergency dispatch protocol (108) to assist the dispatcher (104) communicating with the caller (118). The protocol (108) presents a plurality of interrogatories for the dispatcher (104) to ask the caller (118) to collect information regarding the medical emergency and generate an emergency medical dispatch response by emergency responders based on the collected information. The dispatch center computer system (106) initiates a diagnostic tool (120) which is configured to aid the dispatcher (104) in uniformly collecting information about symptoms of a pandemic illness in a uniform consistent manner. The diagnostic tool (120) presents, to the dispatcher (104), a user interface and provides an instruction via the user interface for the dispatcher (104) to vocally relay to the caller (118) over the telephone to guide the caller in identifying symptoms of the pandemic illness that the patient is manifesting. The diagnostic tool (120) receives dispatcher-entered input that is indicative of information about symptoms of a pandemic illness gathered and relayed by the caller (118). The caller (118) relays the symptom information to the dispatcher (104) vocally over the telephone (116) and the diagnostic tool (120) collects symptom information from the dispatcher (104) entered input and compiles the symptom information into data having a uniform format that can be processed to monitor the spread of the pandemic illness. The dispatch center computer system (106) then transmits the collected symptom information to a data analyzing module that is configured to identify patterns and relationships within data received by the data analyzing module.
Presented are systems and methods for examining patients and generating diagnostic medical data to make automated diagnoses and treatment recommendations to patients and doctors. Various embodiments of the present invention provide patients with diagnostic tools and audio/video guidance to reliably and accurately perform clinical grade diagnostic measurements of key vital signs. In embodiments, this is accomplished by using an automated remote (or local, e.g., in the form of a kiosk) end-to-end medical diagnostic system that monitors equipment usage for accuracy. The diagnostic system analyzes patient responses, measurement data, and patient-related information to generate diagnostic and/or treatment information that may be shared with healthcare professionals and specialists, as needed. Automation provides for timely, hassle-free, and cost-effective health care management that takes the stress out of doctor visits, while delivering personalized health care. The high accuracy of generated diagnostic data improves health care to patients and reduces the risk of medical malpractice for treating physicians.